Effects of dorzolamide on choroidal blood flow, ciliary blood flow, and aqueous production in rabbits

Herbert A. Reitsamer, Barbara Bogner, Birgit Tockner, Jeffrey W. Kiel

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

PURPOSE. To determine the effects of topical dorzolamide (a carbonic anhydrase inhibitor) on choroidal and ciliary blood flow and the relationship between ciliary blood flow and aqueous flow. METHODS. The experiments were performed in four groups of pentobarbital-anesthetized rabbits treated with topical dorzol-amide (2%, 50 μL). In all groups, intraocular pressure (IOP) and mean arterial pressure (MAP) at the eye level were measured continuously by direct cannulation. In group 1, aqueous flow was measured by fluorophotometry before and after dorzol-amide treatment. In group 2, aqueous flow was measured after dorzolamide at normal MAP and while MAP was held constant at 80, 55, or 40 mm Hg with occluders on the aorta and vena cava. In group 3, the same MAP levels were used, and ciliary blood flow was measured transsclerally by laser Doppler flow-metry (LDF). In group 4, choroidal blood flow was measured by LDF with the probe tip positioned in the vitreous over the posterior pole during ramp increases and decreases in MAP before and after dorzolamide. RESULTS. Dorzolamide lowered IOP by 19% (P < 0.01) and aqueous flow by 17% (P < 0.01), and increased ciliary blood flow by 18% (P < 0.01), which was associated with a significant reduction in ciliary vasculature resistance (-7%, P < 0.01). Dorzolamide shifted the relationship between ciliary blood flow and aqueous flow downward relative to the previously determined control relationship in the rabbit. Dorzol-amide did not alter choroidal blood flow, choroidal vascular resistance, or the choroidal pressure flow relationship. CONCLUSIONS. Acute topical dorzolamide is a ciliary vasodilator and has a direct inhibitory effect on aqueous production, but it does not have a detectable effect on choroidal hemodynamics at the posterior pole in the rabbit.

Original languageEnglish (US)
Pages (from-to)2301-2307
Number of pages7
JournalInvestigative Ophthalmology and Visual Science
Volume50
Issue number5
DOIs
StatePublished - 2009

Fingerprint

dorzolamide
Rabbits
Arterial Pressure
Amides
Intraocular Pressure
Lasers
Fluorophotometry
Carbonic Anhydrase Inhibitors
Venae Cavae
Architectural Accessibility
Pentobarbital
Vasodilator Agents
Catheterization
Vascular Resistance
Aorta

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience
  • Medicine(all)

Cite this

Effects of dorzolamide on choroidal blood flow, ciliary blood flow, and aqueous production in rabbits. / Reitsamer, Herbert A.; Bogner, Barbara; Tockner, Birgit; Kiel, Jeffrey W.

In: Investigative Ophthalmology and Visual Science, Vol. 50, No. 5, 2009, p. 2301-2307.

Research output: Contribution to journalArticle

Reitsamer, Herbert A. ; Bogner, Barbara ; Tockner, Birgit ; Kiel, Jeffrey W. / Effects of dorzolamide on choroidal blood flow, ciliary blood flow, and aqueous production in rabbits. In: Investigative Ophthalmology and Visual Science. 2009 ; Vol. 50, No. 5. pp. 2301-2307.
@article{92b75923f67946cd8955eaf5505150a2,
title = "Effects of dorzolamide on choroidal blood flow, ciliary blood flow, and aqueous production in rabbits",
abstract = "PURPOSE. To determine the effects of topical dorzolamide (a carbonic anhydrase inhibitor) on choroidal and ciliary blood flow and the relationship between ciliary blood flow and aqueous flow. METHODS. The experiments were performed in four groups of pentobarbital-anesthetized rabbits treated with topical dorzol-amide (2{\%}, 50 μL). In all groups, intraocular pressure (IOP) and mean arterial pressure (MAP) at the eye level were measured continuously by direct cannulation. In group 1, aqueous flow was measured by fluorophotometry before and after dorzol-amide treatment. In group 2, aqueous flow was measured after dorzolamide at normal MAP and while MAP was held constant at 80, 55, or 40 mm Hg with occluders on the aorta and vena cava. In group 3, the same MAP levels were used, and ciliary blood flow was measured transsclerally by laser Doppler flow-metry (LDF). In group 4, choroidal blood flow was measured by LDF with the probe tip positioned in the vitreous over the posterior pole during ramp increases and decreases in MAP before and after dorzolamide. RESULTS. Dorzolamide lowered IOP by 19{\%} (P < 0.01) and aqueous flow by 17{\%} (P < 0.01), and increased ciliary blood flow by 18{\%} (P < 0.01), which was associated with a significant reduction in ciliary vasculature resistance (-7{\%}, P < 0.01). Dorzolamide shifted the relationship between ciliary blood flow and aqueous flow downward relative to the previously determined control relationship in the rabbit. Dorzol-amide did not alter choroidal blood flow, choroidal vascular resistance, or the choroidal pressure flow relationship. CONCLUSIONS. Acute topical dorzolamide is a ciliary vasodilator and has a direct inhibitory effect on aqueous production, but it does not have a detectable effect on choroidal hemodynamics at the posterior pole in the rabbit.",
author = "Reitsamer, {Herbert A.} and Barbara Bogner and Birgit Tockner and Kiel, {Jeffrey W.}",
year = "2009",
doi = "10.1167/iovs.08-2468",
language = "English (US)",
volume = "50",
pages = "2301--2307",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "5",

}

TY - JOUR

T1 - Effects of dorzolamide on choroidal blood flow, ciliary blood flow, and aqueous production in rabbits

AU - Reitsamer, Herbert A.

AU - Bogner, Barbara

AU - Tockner, Birgit

AU - Kiel, Jeffrey W.

PY - 2009

Y1 - 2009

N2 - PURPOSE. To determine the effects of topical dorzolamide (a carbonic anhydrase inhibitor) on choroidal and ciliary blood flow and the relationship between ciliary blood flow and aqueous flow. METHODS. The experiments were performed in four groups of pentobarbital-anesthetized rabbits treated with topical dorzol-amide (2%, 50 μL). In all groups, intraocular pressure (IOP) and mean arterial pressure (MAP) at the eye level were measured continuously by direct cannulation. In group 1, aqueous flow was measured by fluorophotometry before and after dorzol-amide treatment. In group 2, aqueous flow was measured after dorzolamide at normal MAP and while MAP was held constant at 80, 55, or 40 mm Hg with occluders on the aorta and vena cava. In group 3, the same MAP levels were used, and ciliary blood flow was measured transsclerally by laser Doppler flow-metry (LDF). In group 4, choroidal blood flow was measured by LDF with the probe tip positioned in the vitreous over the posterior pole during ramp increases and decreases in MAP before and after dorzolamide. RESULTS. Dorzolamide lowered IOP by 19% (P < 0.01) and aqueous flow by 17% (P < 0.01), and increased ciliary blood flow by 18% (P < 0.01), which was associated with a significant reduction in ciliary vasculature resistance (-7%, P < 0.01). Dorzolamide shifted the relationship between ciliary blood flow and aqueous flow downward relative to the previously determined control relationship in the rabbit. Dorzol-amide did not alter choroidal blood flow, choroidal vascular resistance, or the choroidal pressure flow relationship. CONCLUSIONS. Acute topical dorzolamide is a ciliary vasodilator and has a direct inhibitory effect on aqueous production, but it does not have a detectable effect on choroidal hemodynamics at the posterior pole in the rabbit.

AB - PURPOSE. To determine the effects of topical dorzolamide (a carbonic anhydrase inhibitor) on choroidal and ciliary blood flow and the relationship between ciliary blood flow and aqueous flow. METHODS. The experiments were performed in four groups of pentobarbital-anesthetized rabbits treated with topical dorzol-amide (2%, 50 μL). In all groups, intraocular pressure (IOP) and mean arterial pressure (MAP) at the eye level were measured continuously by direct cannulation. In group 1, aqueous flow was measured by fluorophotometry before and after dorzol-amide treatment. In group 2, aqueous flow was measured after dorzolamide at normal MAP and while MAP was held constant at 80, 55, or 40 mm Hg with occluders on the aorta and vena cava. In group 3, the same MAP levels were used, and ciliary blood flow was measured transsclerally by laser Doppler flow-metry (LDF). In group 4, choroidal blood flow was measured by LDF with the probe tip positioned in the vitreous over the posterior pole during ramp increases and decreases in MAP before and after dorzolamide. RESULTS. Dorzolamide lowered IOP by 19% (P < 0.01) and aqueous flow by 17% (P < 0.01), and increased ciliary blood flow by 18% (P < 0.01), which was associated with a significant reduction in ciliary vasculature resistance (-7%, P < 0.01). Dorzolamide shifted the relationship between ciliary blood flow and aqueous flow downward relative to the previously determined control relationship in the rabbit. Dorzol-amide did not alter choroidal blood flow, choroidal vascular resistance, or the choroidal pressure flow relationship. CONCLUSIONS. Acute topical dorzolamide is a ciliary vasodilator and has a direct inhibitory effect on aqueous production, but it does not have a detectable effect on choroidal hemodynamics at the posterior pole in the rabbit.

UR - http://www.scopus.com/inward/record.url?scp=65549104355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549104355&partnerID=8YFLogxK

U2 - 10.1167/iovs.08-2468

DO - 10.1167/iovs.08-2468

M3 - Article

C2 - 19182250

AN - SCOPUS:65549104355

VL - 50

SP - 2301

EP - 2307

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 5

ER -